Welcome to our dedicated page for Paysign SEC filings (Ticker: PAYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how prepaid card loads or patient affordability revenues move quarter to quarter can feel like decoding a payments labyrinth. Paysign’s disclosures often span hundreds of pages and multiple form types, each packed with regulatory detail on stored-value balances, healthcare co-pay volumes, and settlement risks. If you have ever searched “Paysign insider trading Form 4 transactions” or wondered why a sudden spike in interchange income shows up deep inside a note to the financials, you know the challenge.
Stock Titan solves that problem. Our AI reads every Paysign quarterly earnings report 10-Q filing, flags segment shifts, and translates revenue recognition footnotes into plain English. Real-time alerts surface “Paysign Form 4 insider transactions real-time”, while concise dashboards answer popular questions like “Paysign annual report 10-K simplified” or “Paysign 8-K material events explained”. You’ll see at a glance where executives exercised options, how cash settlement fees compare year over year, and which material contracts triggered an 8-K.
Use cases go beyond quick summaries. Analysts download redlined comparisons to spot fee-structure changes; portfolio managers set triggers for “Paysign executive stock transactions Form 4”; governance teams review “Paysign proxy statement executive compensation”. Every filing type—10-K, 10-Q, 8-K, DEF 14A, S-8—is updated directly from EDGAR within minutes. And because our platform keeps the question in mind—“understanding Paysign SEC documents with AI” and providing “Paysign earnings report filing analysis” that matters—you save hours and gain confidence before making your next move.
Paysign, Inc. insider Robert Strobo acquired 100,000 shares of restricted common stock on 05/07/2025 at a reported price of $0.00, increasing his beneficial ownership to 347,290 shares. The shares are restricted and will vest in three equal installments: one-third on May 27, 2026, one-third on May 24, 2027, and the final third on May 26, 2028, subject to Strobo's continued service to the company through each vesting date.
The Form 4 was signed by Robert Strobo on 09/26/2025 and identifies his role as Chief Legal Officer and as an officer reporting person. No derivative transactions, dispositions, exercise prices, or additional cash consideration are reported in this filing.
Joan M. Herman, who serves as Executive Vice President, Operations and a director of Paysign, Inc. (PAYS), reported an equity grant on Form 4. On 05/07/2025 she acquired 16,667 shares of restricted common stock at a reported price of $0.000. Following the grant, the filing shows she beneficially owns 838,250 shares in total. The restricted shares vest in three equal installments: 1/3 on May 13, 2026, 1/3 on May 13, 2027 and 1/3 on May 13, 2028, subject to continued service. The Form 4 is signed by Ms. Herman on 09/26/2025.
Paysign, Inc. reported a Form 4 showing that Jeffery Bradford Baker, the company's Chief Financial Officer and a director, was granted 100,000 shares of restricted common stock on 05/07/2025 at a reported price of $0.000. Following the grant, Baker beneficially owns 352,273 shares. The restricted shares vest in three equal installments: one-third on May 29, 2026, one-third on May 20, 2027, and one-third on May 30, 2028, subject to continued service. The Form 4 is signed by Baker on 09/26/2025.
Key results (Q2 2025): Total revenues $19,078,353; gross profit $11,755,165; net income $1,387,761; gross margin 61.6%.
Six months YTD: Revenues $37,676,502; net income $3,973,861; gross margin 62.2%. Total assets $193,896,201; total liabilities $151,688,242; cash and restricted cash $113,913,123.
Drivers and transactions: Revenue growth driven by pharma industry (+$5,079,005; +189.9% Q2; +$11,309,014; +223.3% YTD). Plasma revenue declined (-4.7% Q2; -6.9% YTD). On March 19, 2025 Paysign acquired Gamma Innovation LLC: preliminary purchase consideration $15,558,637; identifiable intangible assets $11,071,000; goodwill $4,487,637; earn-out contingent consideration revised to $990,000.
Paysign, Inc. (PAYS) – Form 4 insider activity
Chief Legal Officer Robert Strobo reported two transactions. On 31 Jul 2025 he vested/exercised 64,000 restricted shares (Code “M”) at $0, lifting his direct holding to 273,811 shares. On 4 Aug 2025 he sold 26,521 common shares in the open market (Code “S”) at a weighted-average price of $7.0851 (range $6.9976–$7.1530). Post-sale he directly owns 247,290 shares.
The stock grant vests 20 % annually from 31 Jul 2022 through 31 Jul 2027. Derivative table shows 128,000 shares still underlying outstanding awards.
- Net change: +37,479 shares retained.
- Portion sold: ≈41 % of newly vested shares.
No earnings, guidance, or other financial disclosures are included.
Paysign, Inc. (PAYS) Form 4 highlights insider activity by CFO Jeffery B. Baker.
- On 07/31/2025 Baker received 64,000 common shares as part of a previously granted restricted stock award; the grant vests 20 % annually from 07/31/2022 through 07/31/2027 and carried a $0 exercise price.
- On 08/04/2025 he sold 30,396 shares at a weighted-average price of $7.0851 (sales occurred within a price range of $6.9976–$7.1530).
Following these transactions Baker directly owns 252,273 common shares and retains derivative rights to 128,000 additional shares tied to the same award. The filing discloses no new option grants, compensation changes or company-specific events and indicates the sale was executed under a Rule 10b5-1 plan. Overall, the activity appears routine, with the executive maintaining a substantial equity stake.
FAQ
What is the current stock price of Paysign (PAYS)?
What is the market cap of Paysign (PAYS)?
